Regencell Bioscience (NASDAQ:RGC) Trading 5.2% Higher – Time to Buy?

Regencell Bioscience Holdings Limited (NASDAQ:RGC)’s stock price traded up 5.2% during mid-day trading on Tuesday . The stock traded as high as $24.84 and last traded at $24.70. 117,312 shares traded hands during trading, a decline of 98% from the average session volume of 7,253,475 shares. The stock had previously closed at $23.48.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Regencell Bioscience in a research note on Monday, December 22nd. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has an average rating of “Sell”.

Regencell Bioscience Stock Up 4.0%

The stock has a 50-day simple moving average of $15.70.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in RGC. Geode Capital Management LLC raised its position in shares of Regencell Bioscience by 5,637.5% in the second quarter. Geode Capital Management LLC now owns 391,066 shares of the company’s stock valued at $6,664,000 after buying an additional 384,250 shares during the last quarter. Squarepoint Ops LLC purchased a new stake in Regencell Bioscience in the 2nd quarter worth approximately $1,701,000. BNP Paribas Financial Markets acquired a new position in Regencell Bioscience in the 2nd quarter valued at $768,000. XTX Topco Ltd acquired a new position in Regencell Bioscience in the 3rd quarter valued at $598,000. Finally, Y Intercept Hong Kong Ltd purchased a new position in shares of Regencell Bioscience during the 2nd quarter worth $222,000. 0.13% of the stock is currently owned by hedge funds and other institutional investors.

About Regencell Bioscience

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.